Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on CHOCOLADEFABRIKEN LINDT-REG. We currently have 7 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
Distinguished performance amongst food players
07 Mar 17
FY update: as a reminder sales grew organically 6% (volume +3.9%, price/mix 2.1%). The reported EBIT was up +8.4% with the EBIT margin up 20bp to 14.4% (broadly in line with our estimates). By division, the EBIT margin improved in Europe +100bp and in ROW +190bp but was weaker for NAFTA -120bp on the back of RS portfolio adjustments, production-line investments and promotional activity (however, these works were necessary for long-term profitable growth in future). L&S opened 60 new chocolate shops and cafés (more than the 20-30 target), mainly in Europe, Canada, Brazil and Japan, pushing its Retail network to 370 outlets. The Global Retail division increased sales by 12.7%. Net income was up 10.2%. Dividend was up 10%. FY17 guidance: organic sales broadly in line with the past year and a further improvement in the EBIT margin. Mid- to long-term guidance is maintained: 6-8% top-line growth with a 20-40bp EBIT margin expansion.
FY trading update: strategic goals kept despite challenging environment
17 Jan 17
Sales grew organically by 6% (H2: 7.6%, in line with our forecast and slightly better than consensus of 5.7%) and 6.8% on reported figures (in line with consensus, FX: 0.8%). Excluding Russell Stover, sales grew organically 7.4%. FY OG by region: Europe +7.4%, NAFTA +3.4% and ROW +10.2% (driven by Japan and Brazil). Global Retail recorded double- digit growth.
Russell Stover portfolio adjustments drag OG but bottom line remains solid
22 Jul 16
L&S released its H1 update. Organic sales stood at 4.4% (cons. 5.3%) and were up +6.6% on reported figures. Weaker than expected OG is linked to adjustments to the Russell Stover portfolio (SKU reduction that does not fit into the strategy, coupled with price increases and decreasing promotional activity). Excluding Russell Stover, organic sales were up 6.6%. OG by region: 5.7%, NAFTA +0.8% (+6.6% excluding the effect of Russell Stover) and ROW +10.2%. The EBIT margin increased by 20bp (better than expected) booking a CHF98.4m operating profit in H1 (in line with expectations). The FY guidance is maintained: 6-8% organic growth and an increase in EBIT of 20-40bp.
Aims to boost its Global Retail Network by 2020
08 Mar 16
L&S has released its FY accounts. As a reminder, at the time of the trading statement, the group reported 7.1% organic sales growth (4.8% in H2). On a FY basis, operating profit stood at CHF518.8m (slightly above consensus and our estimates). The operating margin rose 20bp (10bp better than expected). Net profit increased by 11.2%, and the proposed dividend is up 10.3% to CHF800. For FY16, the group confirms its mid- to long-term guidance: 6-8% organic growth and an increase in EBIT of 20-40bp.
FY trading update: H2 OG disappoints
14 Jan 16
FY trading update. Organic sales growth stood at 7.1% (only 4.8% OG in H2). On the reported figures, sales progressed by 7.9% (negative FX effect stood at 5.6%, in local currencies sales progressed by 13.5%) to CHF 3.65bn. By region, Europe OG was at 5.6%, NAFTA achieved 7.9% OG, whereas ROW OG stood at 11.4%. The group expects the FY operating profit margin to be at least the same level as last year. More details with the full financial statement on 8 March.
18 Aug 15
L&S released its H1 results. As a reminder at its H1 trading update, the company reported 9.4% OG (6.4% in volume and 3% in price/mix) excluding Russell Stover's results. Total sales (including Russell Stover) increased by 17.4% to CHF1,409m with a -7.5% FX effect. Russell Stover's integration added 15.5% to the results. The group grew organically in all regions: Europe 6.9%, NAFTA 10.3% (excl. Russell Stover) and ROW 18.9%. On reported figures, Europe's sales declined by 4.9%, NAFTA's was up by 69.2% (and by 14.9% excluding Russell Stover) whereas ROW delivered 13.3%. EBIT stood at CHF90.6m (in line with our estimates). The EBIT margin was flat yoy with Europe +120bp, NAFTA +20bp and ROW down by 30bp. The group's net income reached CHF65m (+16.5% yoy). L&S confirmed its FY outlook: 6-8% sales OG and 20-40bp EBIT margin expansion once the Russell Stover integration is accomplished.
New Product Development Enhances the Mix
17 Mar 17
Fever Tree’s (FEVR LN, HOLD, T/P 1250p) announces preliminary 2016 results on Tuesday 21st March. We forecast revenue to increase 72.6% to £102.2m in line with the 24th January trading update, and adjusted diluted EPS to continue its positive momentum to 25.2p (23.7p FY2015). Current consensus appears to be 24.0p (Source: Bloomberg).
21 Mar 17
Fever Tree’s (FEVR LN, HOLD, T/P 1250p) preliminary 2016 results this morning included in line EBITDA and diluted EPS. The company reported £35.8m of EBITDA – marginally ahead of our own £35.6m estimate and in front of £34.9m consensus forecast. Adjusted diluted EPS was 23.7p (+104%), consistent with our estimate (23.7p) but slightly below the 24.0p predicted by consensus (source: Bloomberg). Fever Tree holds an analyst presentation at 9.30am.
Panmure Morning Note 20-03-2017
20 Mar 17
Today’s H1FY17 results are in line with our and consensus expectations, and we are therefore maintaining our FY17 and FY18 PBT estimates. We regard this as a resilient performance given the turbulent backdrop. We leave our BUY rating and 150p TP unchanged to reflect our positive view on FIF’s long-term prospects predicated on; (1) FIF’s broad-based business spread across channel, customer and product providing diversification of opportunity and risk; (2) FIF is wellpositioned in the fast-growing areas (e.g. artisan breads, celebration cakes, “food-to-go”/foodservice) of the UK bakery market; and (3) FIF’s market leading position and size to deliver scale advantage to develop its stated growth opportunities (including targeted accretive acquisitions), further supported by FIF’s sound financial position (H1FY17 net debt/EBITDA of 0.8x).
Small Cap Breakfast
23 Mar 17
K3 Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march.
10 for 17
09 Jan 17
As always at the start of a year, there are significant uncertainties about the year ahead but I think in 2017, the level of uncertainly has decisively moved up a gear. In fact, a leading economist at the LSE, Ethan Ilzetzki, was recently quoted as saying “I view the current global economic environment as the most uncertain in modern history”. Wow.
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.